Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.5811/westjem.2018.4.38383 http://scihub22266oqcxt.onion/10.5811/westjem.2018.4.38383 C6040910!6040910!30013696     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       West+J+Emerg+Med 2018 ; 19 (4): 631-4 Nephropedia Template TP {{tp|p=30013696|t=2018. Understanding the Use of Composite Endpoints in Clinical Trials |pdf=|usr=}}{{30013696}} gab.com Text Understanding the Use of Composite Endpoints in Clinical Trials JO: West J Emerg Med http://www.kidney.de/pget.php?&tw=1&pmid=30013696 #FOAvip Clinicians, institutions, healthcare networks, and policymakers use outcomes reported in clinical trials as the basis for medical decision-making when managing individual patients or populations. Therefore, the choice of a valid primary endpoint is crucial for randomized controlled trials (RCT) to demonstrate efficacy of new therapies. Recent improvements in treatment, however, have led to a decline in the morbidity and mortality of several common diseases, resulting in a reduction in relevant outcomes that can be used as clinical trial endpoints. Composite endpoints have been used as a solution to maintain the feasibility of RCTs, particularly when facing low event rates, high cost, and long follow-up. However, the benefits of using composite endpoints must be weighed against the risks of misinterpretation by clinicians and policymakers, as incorrect interpretation may have a detrimental effect on patients and populations. This paper defines a composite endpoint, discusses the rationale for its use, and provides a practical approach to interpreting results to aid in medical decision-making. Twit Text FOAVip Understanding the Use of Composite Endpoints in Clinical Trials ????West J Emerg Med http://www.kidney.de/pget.php?&tw=1&pmid=30013696 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=30013696 #FOAvip English Wikipedia <ref>{{Cite pmid|30013696}}</ref> Understanding the Use of Composite Endpoints in Clinical Trials #MMPMID30013696 McCoy CE West J Emerg Med 2018[Jul]; 19 (4): 631-4 PMID30013696show ga Clinicians, institutions, healthcare networks, and policymakers use outcomes reported in clinical trials as the basis for medical decision-making when managing individual patients or populations. Therefore, the choice of a valid primary endpoint is crucial for randomized controlled trials (RCT) to demonstrate efficacy of new therapies. Recent improvements in treatment, however, have led to a decline in the morbidity and mortality of several common diseases, resulting in a reduction in relevant outcomes that can be used as clinical trial endpoints. Composite endpoints have been used as a solution to maintain the feasibility of RCTs, particularly when facing low event rates, high cost, and long follow-up. However, the benefits of using composite endpoints must be weighed against the risks of misinterpretation by clinicians and policymakers, as incorrect interpretation may have a detrimental effect on patients and populations. This paper defines a composite endpoint, discusses the rationale for its use, and provides a practical approach to interpreting results to aid in medical decision-making. äUnderstanding the Use of Composite Endpoints in Clinical Trials (epmc).pdf DeepDyve Pubget Overpricing